Kuchiba Aya, Tanaka Noriko Y, Ohashi Yasuo
Department of Biostatistics/Epidemiology and Preventive Health Sciences, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Department of Clinical Bioinformatics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
J Hum Genet. 2006;51(12):1046-1054. doi: 10.1007/s10038-006-0057-6. Epub 2006 Sep 27.
Genetic association studies using case-control designs are often done to identify loci associated with disease susceptibility. These studies are often expensive to perform, due to a large number of genetic markers. Several types of two-stage designs are proposed and used from the point of cost effectiveness. We proposed to control the false discovery rate for multiple-testing correction in two-stage designs, using optimal sample sizes and criteria for selecting markers associated with a disease in each stage to minimize the cost of genotyping. The expected power and cost of two-stage designs were compared with those of one-stage designs, under the assumptions that the genetic markers are independent and total sample size is fixed. The results showed that the proposed two-stage procedure usually reduced the cost of genotyping by 40-60%, with a power similar to that of the one-stage designs. In addition, the sample size and selection criteria, which are optimized parameters, are defined as a function of a prior probability that marker-disease association is true. So, the effects of mis-specification of a prior probability on efficiency were also considered.
采用病例对照设计的基因关联研究通常旨在识别与疾病易感性相关的基因座。由于大量的遗传标记,这些研究的实施成本往往很高。从成本效益的角度出发,人们提出并采用了几种两阶段设计。我们建议在两阶段设计中控制多重检验校正的错误发现率,使用最优样本量和在每个阶段选择与疾病相关标记的标准,以尽量降低基因分型成本。在遗传标记相互独立且总样本量固定的假设下,将两阶段设计的预期效能和成本与单阶段设计进行了比较。结果表明,所提出的两阶段方法通常可将基因分型成本降低40%至60%,效能与单阶段设计相近。此外,作为优化参数的样本量和选择标准被定义为标记与疾病关联为真的先验概率的函数。因此,还考虑了先验概率错误设定对效率的影响。